Afficher la couverture 'COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models | Maisonnasse, Pauline' en grand format
/5

0 avis

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

Archive ouverte

Maisonnasse, Pauline | Aldon, Yoann | Marc, Aurélien | Marlin, Romain | Dereuddre-Bosquet, Nathalie | Kuzmina, Natalia | Freyn, Alec | Snitselaar, Jonne | Gonçalves, Antonio | Caniels, Tom | Burger, Judith | Poniman, Meliawati | Bontjer, Ilja | Chesnais, Virginie | Diry, Ségolène | Iershov, Anton | Ronk, Adam | Jangra, Sonia | Rathnasinghe, Raveen | Brouwer, Philip | Bijl, Tom | van Schooten, Jelle | Brinkkemper, Mitch | Liu, Hejun | Yuan, Meng | Mire, Chad | van Breemen, Mariëlle | Contreras, Vanessa | Naninck, Thibaut | Lemaître, Julien | Kahlaoui, Nidhal | Relouzat, Francis | Chapon, Catherine | Ho Tsong Fang, Raphaël | Mcdanal, Charlene | Osei-Twum, Mary | St-Amant, Natalie | Gagnon, Luc | Montefiori, David | Wilson, Ian | Ginoux, Eric | de Bree, Godelieve | García-Sastre, Adolfo | Schotsaert, Michael | Coughlan, Lynda | Bukreyev, Alexander | van der Werf, Sylvie | Guedj, Jérémie | Sanders, Rogier | van Gils, Marit | Le Grand, Roger

Edité par CCSD ; Nature Publishing Group -

International audience. Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the in vivo prophylactic and therapeutic effect of COVA1-18, a neutralizing antibody highly potent against the B.1.1.7 isolate. In both prophylactic and therapeutic settings, SARS-CoV-2 remains undetectable in the lungs of treated hACE2 mice. Therapeutic treatment also causes a reduction in viral loads in the lungs of Syrian hamsters. When administered at 10 mg kg-1 one day prior to a high dose SARS-CoV-2 challenge in cynomolgus macaques, COVA1-18 shows very strong antiviral activity in the upper respiratory compartments. Using a mathematical model, we estimate that COVA1-18 reduces viral infectivity by more than 95% in these compartments, preventing lymphopenia and extensive lung lesions. Our findings demonstrate that COVA1-18 has a strong antiviral activity in three preclinical models and could be a valuable candidate for further clinical evaluation.

Suggestions

Du même auteur

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

Archive ouverte | Brouwer, Philip J.M. | CCSD

International audience

Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection

Archive ouverte | Sulbaran, Guidenn | CCSD

International audience. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused an ongoing global health crisis. Here, we present as a vaccine candidate synthetic SARS-CoV-2 spike (S) gl...

Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques

Archive ouverte | Marlin, Romain | CCSD

International audience. Abstract Achieving sufficient worldwide vaccination coverage against SARS-CoV-2 will require additional approaches to currently approved viral vector and mRNA vaccines. Subunit vaccines may h...

Chargement des enrichissements...